chlorphentermine

Chlorphentermine
Systematic (IUPAC) name
	1-(4-chlorophenyl)-2-methylpropan-2-amine
Clinical data
Legal status	Schedule III (US);
Routes of; administration	Oral, Insufflated, Rectal
Pharmacokinetic data
Biological half-life	40 hours
Excretion	Renal
Identifiers
CAS Registry Number	461-78-9 151-06-4
ATC code	A08AA
PubChem	CID: 10007
DrugBank	DB01556
ChemSpider	9613
UNII	NHW07912O7
KEGG	C07559
ChEMBL	CHEMBL1201269
Synonyms	p-Chloro-α,α-dimethylphenethylamine
Chemical data
Formula	C10H14ClN
Molecular mass	183.68 g/mol
	SMILES Clc1ccc(cc1)CC(N)(C)C;
	InChI InChI=1S/C10H14ClN/c1-10(2,12)7-8-3-5-9(11)6-4-8/h3-6H,7,12H2,1-2H3 ; Key:ZCKAMNXUHHNZLN-UHFFFAOYSA-N ;
(what is this?) (verify)

クロルフェンテルミン

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/06/25 06:12:16」(JST)

wiki en

[Wiki en表示]

Chlorphentermine (trade names Apsedon, Desopimon, Lucofen) is an appetite suppressant of the phenethylamine class. Developed in 1962, it is the 4-chloro derivative of the better known appetite suppressant phentermine,^[1] which is still in current use.

Chlorphentermine itself is a relatively weak stimulant with little abuse potential, but is classed as a Schedule III drug in the USA due mainly to its similarity to other appetite suppressants such as diethylpropion which have been more widely abused. It is no longer used due mainly to safety concerns, as it has a serotonergic effects profile similar to other withdrawn appetite suppressants such as fenfluramine and aminorex which were found to cause pulmonary hypertension and cardiac fibrosis following prolonged use.^[2]

References

^ Gylys JA, Hart JJ, Warren MR. Chlorphentermine, a new anorectic agent. Journal of Pharmacology and Experimental Therapeutics. 1962 Sep;137:365-73.
^ Rothman RB, Ayestas MA, Dersch CM, Baumann MH. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Circulation. 1999 Aug 24;100(8):869-75.

English Journal

Screening for amphetamine and amphetamine-type drugs in doping analysis by liquid chromatography/mass spectrometry.

Deventer K1, Van Eenoo P, Delbeke FT.Author information 1Ghent University, Department of Clinical Chemistry, Microbiology and Immunology, Doping Control Laboratory (DoCoLab), Technologiepark Zwijnaarde, Belgium. Koen.Deventer@UGent.beAbstractA selective and sensitive method for the qualitative screening of urine samples for 27 amphetamine and amphetamine-type drugs in the field of doping analysis is described. The method consists of a liquid-liquid extraction with diethyl ether at pH 14 and analysis of the extracts with a LCQ-Deca mass spectrometer equipped with an atmospheric pressure chemical ionisation interface, operated in positive ionisation mode. The total run time was 15 min. All compounds were analysed in MS2 or MS3. The detection limit for all compounds was lower than 25 ng/mL except for chlorphentermine (detection limit: 250 ng/mL).
Rapid communications in mass spectrometry : RCM.Rapid Commun Mass Spectrom.2006;20(5):877-82.
A selective and sensitive method for the qualitative screening of urine samples for 27 amphetamine and amphetamine-type drugs in the field of doping analysis is described. The method consists of a liquid-liquid extraction with diethyl ether at pH 14 and analysis of the extracts with a LCQ-Deca mass
PMID 16470715

[The role of pharmacotherapy for treatment of obesity in adults].

Czupryniak L, Drzewoski J.AbstractObesity is one of the pathologies with ever-increasing prevalence in modern societies. Its occurrence is strongly associated with increased risk of developing diabetes mellitus, atherosclerosis, hypertension, stroke, heart and respiratory failure, breast, prostate and gut cancer, gall stones, arthropathy. Obesity is common in Polish population. Obesity treatment is difficult and frustrating. It consists of several parts like diet, increased physical activity, lifestyle changes, drug therapy and surgery. However, obesity treatment is very often a failure, mostly because of discouraging long-term results and the necessity of intensive patient's involvement in the therapy. For many patients and doctors weight-decreasing agents look promising. The groups of anti-obesity drugs are presented in the article, with special reference to serotoninergic agents and intestinal lipase inhibitors. The prospects for new anti-obesity agents are discussed. Nevertheless, despite intensive research on obesity, we are still waiting for the development of an effective and safe drugs helping lose weight.
Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego.Pol Merkur Lekarski.2000 Nov;9(53):741-5.
Obesity is one of the pathologies with ever-increasing prevalence in modern societies. Its occurrence is strongly associated with increased risk of developing diabetes mellitus, atherosclerosis, hypertension, stroke, heart and respiratory failure, breast, prostate and gut cancer, gall stones, arthro
PMID 11204319

Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: therapeutic implications.

Baumann MH1, Ayestas MA, Dersch CM, Brockington A, Rice KC, Rothman RB.Author information 1Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland 21224, USA.AbstractCombined administration of the amphetamine analogs phentermine and fenfluramine (PHEN/FEN) has been used in the treatment of obesity. While these medications are thought to modulate monoamine transmission, the precise neurochemical effects of the PHEN/FEN mixture have not been extensively studied. To assess the mechanism of PHEN/FEN action, in vivo microdialysis studies were performed in the nucleus accumbens of conscious freely moving rats. A series of amphetamine derivatives including phentermine, chlorphentermine, fenfluramine, and PHEN/FEN (1:1 ratio), were infused locally into the accumbens via reverse-dialysis (1, 10, 100 microM) or injected systemically (1 mg/kg, ip). Dialysate samples were assayed for dopamine (DA) and serotonin (5-HT) by high-performance liquid chromatography with electrochemical detection. When infused locally, phentermine preferentially increased extracellular DA, whereas fenfluramine selectively increased extracellular 5-HT. Local administration of chlorphentermine or the PHEN/FEN mixture caused parallel elevations of both transmitters. Analogous results were obtained when the drugs were injected systemically. Phentermine stimulated robust locomotor activity in mice, whereas chlorphentermine and fenfluramine did not. PHEN/FEN caused modest locomotor stimulation after a low dose, but had no effect at the highest dose. Accumulating evidence suggests that chronic drug and alcohol abuse is associated with deficits in both DA and 5-HT neuronal function. Thus, dual activation of DA and 5-HT neurotransmission with monoamine releasing agents may be an effective treatment strategy for substance use disorders, as well as for obesity. Synapse 36:102-113, 2000. Published 2000 Wiley-Liss, Inc.
Synapse (New York, N.Y.).Synapse.2000 May;36(2):102-13.
Combined administration of the amphetamine analogs phentermine and fenfluramine (PHEN/FEN) has been used in the treatment of obesity. While these medications are thought to modulate monoamine transmission, the precise neurochemical effects of the PHEN/FEN mixture have not been extensively studied. T
PMID 10767057